Selecta RussiaSite MapContact Us

New Class of Vaccines to Promote
Optimal Immune Response to Disease

At Selecta Biosciences, we are developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic applications.

Our proprietary technology platform is based on innovations in nanotechnology and immunology discovered at MIT and Harvard Medical School. Selecta's platform is designed to create robust immune responses to a wide range of antigens while limiting adverse events.

We are focusing on building a pipeline with a broad range of product candidates in oncology, neuroscience, infectious diseases, autoimmune diseases, and allergies. Our initial product candidate is a first-in-class synthetic vaccine against nicotine for the critically underserved worldwide market of smoking cessation and relapse prevention.

We are developing our novel targeted vaccines and immunotherapeutics for worldwide markets at our facilities in Watertown, Massachusetts, and Moscow, Russia. Learn More blue_arrow

News

  • November 21, 2011 – Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068. Read More red_arrow
  • October 27, 2011– Selecta Announces $47.25 Million Financing. Read More red_arrow
  • October 27, 2011– RUSNANO invests in Selecta Biosciences and BIND Biosciences. Read More red_arrow
  • September 6, 2011 Picture2 – FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech.  Read More red_arrow
  • August 31, 2011 – Selecta Biosciences Awarded Subcontract to Develop a Synthetic Nanoparticle Vaccine for Malaria. Read More red_arrow
  • June 9, 2011 – The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes. Read More red_arrow

Careers

  • Director/Sr. Director - Quality Assurance (USA). Read More red_arrow
  • Director/Sr. Director - Analytical Development (USA). Read More red_arrow
  • Director – Biology/Immunobiology (Russia). Read More red_arrow
  • Director/Sr. Scientist – Chemical Synthesis (Russia). Read More red_arrow
  • Director/Sr. Scientist – Analytical Development (Russia). Read More red_arrow
  • Director/Sr. Scientist– Formulation Development (Russia). Read More red_arrow

© 2012 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email: info@selectabio.com
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.